topotecan has been researched along with Carcinogenesis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aroonroch, R; Boontawon, T; Chaitankar, V; Chittavanich, P; Hongeng, S; Jinawath, N; Kaewkhaw, R; Rojanaporn, D; Saengwimol, D; Thammachote, W | 1 |
Bernhardt, G; Brockhoff, G; Buschauer, A; Huber, S; Wege, AK | 1 |
2 other study(ies) available for topotecan and Carcinogenesis
Article | Year |
---|---|
A three-dimensional organoid model recapitulates tumorigenic aspects and drug responses of advanced human retinoblastoma.
Topics: Antineoplastic Agents; Carcinogenesis; Child, Preschool; DNA Copy Number Variations; Gene Expression Regulation, Neoplastic; Humans; Infant; Melphalan; Models, Biological; Neoplasm Staging; Organoids; Retinal Neoplasms; Retinoblastoma; Topotecan | 2018 |
Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity.
Topics: Animals; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carcinogenesis; CD24 Antigen; Cell Adhesion Molecules; Cell Line, Tumor; Epithelial Cell Adhesion Molecule; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Proteins; Receptor, ErbB-2; Topotecan | 2015 |